Researchers have called on European policymakers to make adequate resources available to tackle pancreatic cancer, a disease that is almost invariably fatal and where little progress has been made over the past 40 years. The latest predictions for cancer deaths in the EU and UK for 2021, published in the leading cancer journal Annals of Oncology, show that pancreatic death rates are predicted to remain approximately stable for men, but continue to rise in women in most EU countries.
New research opens the possibility that targeting the enzyme MAPK4 in human prostate cancer might provide a novel therapeutic strategy for this disease that is the second leading cause of cancer death in American men.
Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.
A new review published in Cancer Reports examines the biological differences in the development of prostate cancer across ethnicities.
Using a 185 metre beamline at the Diamond synchrotron, researchers could see how Osmium, a rare precious metal that could be used for cancer treatments, reacts in a single human lung cancer cell. This is a major step forward in discovering new anti-cancer drugs for researchers at the University of Warwick.
A new system can detect the chemical and microbial content of an air sample with even greater sensitivity than a dog's nose. Researchers at MIT and elsewhere coupled this to a machine-learning process that can identify the distinctive characteristics of the disease-bearing samples.
A new study led by researchers at the UCLA Jonsson Comprehensive Cancer Center helps identify which patients with prostate cancer will benefit most from the use of prostate-specific membrane antigen PET imaging, PSMA PET, a novel imaging technique that recently was approved by the U.S. Food and Drug Administration.
Oncotarget recently published "AKT isoforms have discrete expression in triple negative breast cancers and roles in cisplatin sensitivity" which reported that the authors investigated the expression and net effect of the individual isoforms in triple negative breast cancers and response to cisplatin treatment using cellular, mice models and clinical samples.
The aim of this Oncotarget review is to define the complex crosstalk between these two cell types and to highlight potential future anti-cancer strategies
Additional animal studies revealed that co-administration of PolyHb with cisplatin attenuated tumor growth without alleviating hypoxia